GEN Exclusives

More »

GEN News Highlights

More »
Mar 1, 2007

KineMed and Roche Enter Biomarker Collaboration

  • KineMed and Roche will collaborate to jointly validate KineMed's technology that helps transfer therapeutic agents into advanced clinical studies. KineMarker™ measures the on-mechanism activity of compounds in whole body systems in animals and man.

    The companies will clinically validate the KineMarker of collagen synthesis, a therapeutic target underlying tissue fibrosis, in an undisclosed disease area.

    “Fibrosis is a critical process underlying important diseases affecting major organ systems, including the lungs, kidneys, and liver,” points out David Fineman, president and CEO of KineMed. “The research collaboration with Roche will help to establish our approach as a possible surrogate for an important indication and as a means for monitoring on-mechanism activity of drug candidates in ensuing clinical studies.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »